First Trust Advisors LP boosted its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 106.7% during the first quarter, Holdings Channel reports. The fund owned 36,438 shares of the life sciences company’s stock after buying an additional 18,810 shares during the period. First Trust Advisors LP’s holdings in Integra LifeSciences Holdings Corporation were worth $1,535,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new position in Integra LifeSciences Holdings Corporation during the fourth quarter valued at approximately $12,288,000. Two Sigma Investments LP increased its position in Integra LifeSciences Holdings Corporation by 104.5% in the fourth quarter. Two Sigma Investments LP now owns 257,057 shares of the life sciences company’s stock valued at $22,053,000 after buying an additional 131,341 shares during the last quarter. Thrivent Financial for Lutherans increased its position in Integra LifeSciences Holdings Corporation by 5.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 16,080 shares of the life sciences company’s stock valued at $1,380,000 after buying an additional 860 shares during the last quarter. State Street Corp increased its position in Integra LifeSciences Holdings Corporation by 6.2% in the fourth quarter. State Street Corp now owns 691,617 shares of the life sciences company’s stock valued at $59,334,000 after buying an additional 40,545 shares during the last quarter. Finally, First Mercantile Trust Co. purchased a new position in Integra LifeSciences Holdings Corporation during the first quarter valued at approximately $279,000. Institutional investors and hedge funds own 89.74% of the company’s stock.

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) opened at 53.67 on Tuesday. The stock has a market cap of $4.06 billion, a P/E ratio of 63.89 and a beta of 0.76. The firm’s 50 day moving average price is $49.09 and its 200 day moving average price is $50.43. Integra LifeSciences Holdings Corporation has a 52-week low of $37.38 and a 52-week high of $53.84.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its earnings results on Wednesday, April 26th. The life sciences company reported $0.39 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by $0.01. Integra LifeSciences Holdings Corporation had a net margin of 6.66% and a return on equity of 16.67%. The firm had revenue of $258.60 million for the quarter, compared to analysts’ expectations of $254.19 million. During the same quarter last year, the firm posted $0.38 EPS. The firm’s quarterly revenue was up 9.2% compared to the same quarter last year. On average, analysts expect that Integra LifeSciences Holdings Corporation will post $1.92 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/06/20/first-trust-advisors-lp-raises-stake-in-integra-lifesciences-holdings-corporation-iart.html.

IART has been the topic of several research analyst reports. Piper Jaffray Companies reiterated an “overweight” rating and issued a $47.00 price objective on shares of Integra LifeSciences Holdings Corporation in a research note on Wednesday, March 22nd. ValuEngine downgraded Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Jefferies Group LLC increased their target price on Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $54.00 target price on Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research report on Monday, May 15th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $48.00 target price (up previously from $46.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, May 2nd. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Integra LifeSciences Holdings Corporation currently has a consensus rating of “Buy” and a consensus price target of $49.50.

In related news, Director James M. Sullivan sold 15,658 shares of Integra LifeSciences Holdings Corporation stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $45.89, for a total transaction of $718,545.62. Following the transaction, the director now owns 70,154 shares in the company, valued at approximately $3,219,367.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Stuart Essig sold 135,000 shares of Integra LifeSciences Holdings Corporation stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $49.90, for a total transaction of $6,736,500.00. Following the transaction, the director now owns 2,077,475 shares in the company, valued at approximately $103,666,002.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 304,523 shares of company stock worth $14,812,988. 21.40% of the stock is owned by corporate insiders.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.